{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T09:05:24Z","timestamp":1776071124464,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The transcription factor MYC is a key regulator of cellular proliferation and metabolism and is frequently dysregulated in malignancies such as multiple myeloma (MM). Despite its clinical relevance, direct therapeutic targeting of MYC remains limited, emphasizing the need to identify upstream regulators that control endogenous MYC expression. To systematically uncover such regulators, we developed a genome-wide CRISPR-Cas9 loss-of-function screening approach, employing a custom-engineered MM reporter cell line (RPMI8226-F11), in which oncogenic MYC protein was endogenously tagged with EGFP (referred to as GFP). This fluorescent readout enabled a direct, quantitative assessment of endogenous MYC expression levels. A pooled genome-wide sgRNA library was introduced, and cells were sorted based on GFP fluorescent intensity to reflect varying MYC levels. Next-generation sequencing of sgRNA distributions across sorted populations enabled the identification of candidate MYC regulators. Validation of screen hits, including the established MYC activator IRF4 and repressor FBXW7, confirmed the reliability of our system. To further dissect regulatory networks, we performed an overrepresentation analysis of target genes, which revealed the enrichment of Mediator complex subunits among MYC activators and ubiquitin\u2013proteasome pathway components among MYC repressors. Functional validation of prioritized hits\u2014MED30 (Mediator complex) and UBE3C (E3 ubiquitin ligase)\u2014demonstrated a strong impact on endogenous MYC levels. Notably, the knockout of UBE3C markedly increased MYC expression, whereas its paralogs, UBE3A and UBE3B, showed no measurable effect, suggesting a specific regulatory role for UBE3C in MM cells. Together, our study provides a comprehensive CRISPR screen-based resource for the discovery of MYC regulators and highlights UBE3C as a potential therapeutic node for modulating MYC expression in MM.<\/jats:p>","DOI":"10.1038\/s41598-026-47974-w","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:53:08Z","timestamp":1775893988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Endogenous protein tagging coupled with a CRISPR screening approach identifies UBE3C as a potential MYC oncogene regulator"],"prefix":"10.1038","volume":"16","author":[{"given":"Marcel","family":"Seibert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Kurrle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sifora","family":"Kaleab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Wempe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"von Metzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Schn\u00fctgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"47974_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semcdb.2015.08.003","volume":"43","author":"AL Hsieh","year":"2015","unstructured":"Hsieh, A. L., Walton, Z. E., Altman, B. J., Stine, Z. E. & Dang, C. V. MYC and metabolism on the path to cancer. Semin. Cell Dev. Biol. 43, 11\u201321. https:\/\/doi.org\/10.1016\/j.semcdb.2015.08.003 (2015).","journal-title":"Semin. Cell Dev. Biol."},{"issue":"6","key":"47974_CR2","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41375-018-0036-x","volume":"32","author":"KK Jovanovi\u0107","year":"2018","unstructured":"Jovanovi\u0107, K. K. et al. Targeting MYC in multiple myeloma. Leukemia 32(6), 1295\u20131306. https:\/\/doi.org\/10.1038\/s41375-018-0036-x (2018).","journal-title":"Leukemia"},{"issue":"4","key":"47974_CR3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.20517\/CDR.2021.55","volume":"4","author":"S Mart\u00ednez-Mart\u00edn","year":"2021","unstructured":"Mart\u00ednez-Mart\u00edn, S. & Soucek, L. MYC inhibitors in multiple myeloma. Cancer Drug Resist. 4(4), 842. https:\/\/doi.org\/10.20517\/CDR.2021.55 (2021).","journal-title":"Cancer Drug Resist."},{"issue":"6","key":"47974_CR4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/J.CELL.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6), 904\u2013917. https:\/\/doi.org\/10.1016\/J.CELL.2011.08.017 (2011).","journal-title":"Cell"},{"key":"47974_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2020.621093","author":"Y Sun","year":"2021","unstructured":"Sun, Y. et al. Safety and efficacy of bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: A systematic study of clinical trials. Front. Pharmacol. https:\/\/doi.org\/10.3389\/FPHAR.2020.621093 (2021).","journal-title":"Front. Pharmacol."},{"issue":"12","key":"47974_CR6","first-page":"3507","volume":"62","author":"L Soucek","year":"2002","unstructured":"Soucek, L. et al. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res 62(12), 3507\u20133510 (2002).","journal-title":"Cancer Res"},{"key":"47974_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0022284","author":"M Savino","year":"2011","unstructured":"Savino, M. et al. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS ONE https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0022284 (2011).","journal-title":"PLoS ONE"},{"issue":"3","key":"47974_CR8","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/S41591-024-02805-1","volume":"30","author":"E Garralda","year":"2024","unstructured":"Garralda, E. et al. MYC targeting by OMO-103 in solid tumors: A phase 1 trial. Nat. Med. 30(3), 762\u2013771. https:\/\/doi.org\/10.1038\/S41591-024-02805-1 (2024).","journal-title":"Nat. Med."},{"issue":"1","key":"47974_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3324\/HAEMATOL.2018.191262","volume":"104","author":"K Ishiguro","year":"2019","unstructured":"Ishiguro, K. et al. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling. Haematologica 104(1), 155\u2013165. https:\/\/doi.org\/10.3324\/HAEMATOL.2018.191262 (2019).","journal-title":"Haematologica"},{"key":"47974_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/S41420-020-00400-0","author":"K Ishiguro","year":"2021","unstructured":"Ishiguro, K. et al. Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis. Cell Death Discov. https:\/\/doi.org\/10.1038\/S41420-020-00400-0 (2021).","journal-title":"Cell Death Discov."},{"issue":"5","key":"47974_CR11","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1158\/1535-7163.MCT-12-0066","volume":"11","author":"HL Huang","year":"2012","unstructured":"Huang, H. L. et al. Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. Mol. Cancer Ther. 11(5), 1155\u20131165. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-0066 (2012).","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"47974_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/NMETH.1199","volume":"5","author":"I Poser","year":"2008","unstructured":"Poser, I. et al. BAC TransgeneOmics: A high-throughput method for exploration of protein function in mammals. Nat. Methods 5(5), 409\u2013415. https:\/\/doi.org\/10.1038\/NMETH.1199 (2008).","journal-title":"Nat. Methods"},{"key":"47974_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0003647","author":"C Engler","year":"2008","unstructured":"Engler, C., Kandzia, R. & Marillonnet, S. A one pot, one step, precision cloning method with high throughput capability. PLoS ONE https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0003647 (2008).","journal-title":"PLoS ONE"},{"issue":"1","key":"47974_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/NPROT.2006.37","volume":"1","author":"G Tiscornia","year":"2006","unstructured":"Tiscornia, G., Singer, O. & Verma, I. M. Production and purification of lentiviral vectors. Nat. Protoc. 1(1), 241\u2013245. https:\/\/doi.org\/10.1038\/NPROT.2006.37 (2006).","journal-title":"Nat. Protoc."},{"key":"47974_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/J.YMETH.2019.02.018","volume":"164-165","author":"FMB Th\u00f6ne","year":"2019","unstructured":"Th\u00f6ne, F. M. B., Kurrle, N. S., von Melchner, H. & Schn\u00fctgen, F. CRISPR\/Cas9-mediated generic protein tagging in mammalian cells. Methods 164\u2013165, 59\u201366. https:\/\/doi.org\/10.1016\/J.YMETH.2019.02.018 (2019).","journal-title":"Methods"},{"issue":"4998","key":"47974_CR16","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1126\/SCIENCE.2006410","volume":"251","author":"EM Blackwood","year":"1991","unstructured":"Blackwood, E. M. & Eisenman, R. N. Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251(4998), 1211\u20131217. https:\/\/doi.org\/10.1126\/SCIENCE.2006410 (1991).","journal-title":"Science"},{"issue":"3","key":"47974_CR17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/0092-8674(91)90457-A","volume":"65","author":"GC Prendergast","year":"1991","unstructured":"Prendergast, G. C., Lawe, D. & Ziff, E. B. Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation. Cell 65(3), 395\u2013407. https:\/\/doi.org\/10.1016\/0092-8674(91)90457-A (1991).","journal-title":"Cell"},{"issue":"W1","key":"47974_CR18","doi-asserted-by":"publisher","first-page":"W191","DOI":"10.1093\/NAR\/GKZ369","volume":"47","author":"U Raudvere","year":"2019","unstructured":"Raudvere, U. et al. g:Profiler: A web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 47(W1), W191\u2013W198. https:\/\/doi.org\/10.1093\/NAR\/GKZ369 (2019).","journal-title":"Nucleic Acids Res."},{"issue":"18","key":"47974_CR19","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1093\/BIOINFORMATICS\/BTH456","volume":"20","author":"EI Boyle","year":"2004","unstructured":"Boyle, E. I. et al. GO::TermFinder\u2013open source software for accessing gene ontology information and finding significantly enriched gene ontology terms associated with a list of genes. Bioinformatics 20(18), 3710\u20133715. https:\/\/doi.org\/10.1093\/BIOINFORMATICS\/BTH456 (2004).","journal-title":"Bioinformatics"},{"issue":"7327","key":"47974_CR20","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/NATURE09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468(7327), 1067\u20131073. https:\/\/doi.org\/10.1038\/NATURE09504 (2010).","journal-title":"Nature"},{"issue":"3","key":"47974_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41596-018-0113-7","volume":"14","author":"B Wang","year":"2019","unstructured":"Wang, B. et al. Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute. Nat. Protoc. 14(3), 756\u2013780. https:\/\/doi.org\/10.1038\/s41596-018-0113-7 (2019).","journal-title":"Nat. Protoc."},{"issue":"48","key":"47974_CR22","doi-asserted-by":"publisher","first-page":"34575","DOI":"10.1074\/JBC.M113.499350","volume":"288","author":"BW Chu","year":"2013","unstructured":"Chu, B. W. et al. The E3 ubiquitin ligase UBE3C enhances proteasome processivity by ubiquitinating partially proteolyzed substrates. J. Biol. Chem. 288(48), 34575\u201334587. https:\/\/doi.org\/10.1074\/JBC.M113.499350 (2013).","journal-title":"J. Biol. Chem."},{"issue":"17","key":"47974_CR23","doi-asserted-by":"publisher","first-page":"E3404","DOI":"10.1073\/PNAS.1701734114","volume":"114","author":"CL Kuo","year":"2017","unstructured":"Kuo, C. L. & Goldberg, A. L. Ubiquitinated proteins promote the association of proteasomes with the deubiquitinating enzyme Usp14 and the ubiquitin ligase Ube3c. Proc. Natl. Acad. Sci. USA 114(17), E3404\u2013E3413. https:\/\/doi.org\/10.1073\/PNAS.1701734114 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"47974_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-20107-1","volume":"11","author":"K Li","year":"2020","unstructured":"Li, K. et al. TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation. Nat. Commun. 11(1), 1\u201320. https:\/\/doi.org\/10.1038\/s41467-020-20107-1 (2020).","journal-title":"Nat. Commun."},{"issue":"11","key":"47974_CR25","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41580-022-00498-3","volume":"23","author":"WF Richter","year":"2022","unstructured":"Richter, W. F., Nayak, S., Iwasa, J. & Taatjes, D. J. The mediator complex as a master regulator of transcription by RNA polymerase II. Nat. Rev. Mol. Cell Biol. 23 (11), 732\u2013749. https:\/\/doi.org\/10.1038\/s41580-022-00498-3 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"10","key":"47974_CR26","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1038\/SJ.EMBOJ.7600217","volume":"23","author":"M Yada","year":"2004","unstructured":"Yada, M. et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 23(10), 2116\u20132125. https:\/\/doi.org\/10.1038\/SJ.EMBOJ.7600217 (2004).","journal-title":"EMBO J."},{"issue":"7","key":"47974_CR27","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/J.CELL.2013.05.041","volume":"153","author":"B King","year":"2013","unstructured":"King, B. et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 153(7), 1552. https:\/\/doi.org\/10.1016\/J.CELL.2013.05.041 (2013).","journal-title":"Cell"},{"issue":"5","key":"47974_CR28","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.18632\/ONCOTARGET.3203","volume":"6","author":"M Sato","year":"2015","unstructured":"Sato, M. et al. MYC is a critical target of FBXW7. Oncotarget 6(5), 3292. https:\/\/doi.org\/10.18632\/ONCOTARGET.3203 (2015).","journal-title":"Oncotarget"},{"key":"47974_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2021.679445","author":"XX Sun","year":"2021","unstructured":"Sun, X. X., Li, Y., Sears, R. C. & Dai, M. S. Targeting the MYC ubiquitination-proteasome degradation pathway for cancer therapy. Front. Oncol. https:\/\/doi.org\/10.3389\/FONC.2021.679445 (2021).","journal-title":"Front. Oncol."},{"issue":"7885","key":"47974_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41586-021-04035-8","volume":"599","author":"M de Almeida","year":"2021","unstructured":"de Almeida, M. et al. AKIRIN2 controls the nuclear import of proteasomes in vertebrates. Nature 599(7885), 491\u2013496. https:\/\/doi.org\/10.1038\/s41586-021-04035-8 (2021).","journal-title":"Nature"},{"issue":"4","key":"47974_CR31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/1873-3468.14296","volume":"596","author":"M Nagasaka","year":"2022","unstructured":"Nagasaka, M. et al. The deubiquitinating enzyme USP17 regulates c-Myc levels and controls cell proliferation and glycolysis. FEBS Lett. 596(4), 465\u2013478. https:\/\/doi.org\/10.1002\/1873-3468.14296 (2022).","journal-title":"FEBS Lett."},{"key":"47974_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-7-292","author":"JM Shin","year":"2006","unstructured":"Shin, J. M., Yoo, K. J., Kim, M. S., Kim, D. & Baek, K. H. Hyaluronan- and RNA-binding deubiquitinating enzymes of USP17 family members associated with cell viability. BMC Genom. https:\/\/doi.org\/10.1186\/1471-2164-7-292 (2006).","journal-title":"BMC Genom."},{"issue":"17","key":"47974_CR33","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1182\/BLOOD-2010-02-267344","volume":"117","author":"J Jakubikova","year":"2011","unstructured":"Jakubikova, J. et al. Lenalidomide targets clonogenic side population in multiple myeloma: Pathophysiologic and clinical implications. Blood 117(17), 4409. https:\/\/doi.org\/10.1182\/BLOOD-2010-02-267344 (2011).","journal-title":"Blood"},{"issue":"3","key":"47974_CR34","doi-asserted-by":"publisher","first-page":"56954","DOI":"10.1371\/JOURNAL.PONE.0056954","volume":"8","author":"M Nara","year":"2013","unstructured":"Nara, M. et al. Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells. PLoS ONE 8(3), 56954. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0056954 (2013).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47974-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47974-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47974-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:23:29Z","timestamp":1776068609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47974-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47974"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47974-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12194"}}